Why the study?
Do potent ADP-receptor antagonists (prasugrel or ticagrelor) reduce ischemic periprocedural complications compared to clopidogrel in patients undergoing PCI?
Do potent ADP-receptor antagonists (prasugrel or ticagrelor) reduce ischemic periprocedural complications compared to clopidogrel in patients undergoing PCI?
No takes yet. Share an insight, caveat, or question.
Potent ADP-receptor antagonists like prasugrel and ticagrelor reduce ischemic complications during PCI compared to clopidogrel, but increase bleeding risk.
Lange et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: